Researchers in Sweden have developed a vaccine that helps improve the symptoms of people with mild to moderate Alzheimer’s disease.
The study, published in Lancet Neurology, says this is a breakthrough in the search for a cure to the dementia disease.
The researchers noted the vaccine focuses on the amyloid precursor protein, which resides in the outer membrane of nerve cells and that, instead of being broken down, can form a harmful substance called beta-amyloid, which accumulates as plaques and kills brain cells.
In the second clinical trial in humans, the researchers found 80% of patients developed their own protective antibodies against beta-amyloid without suffering any side-effects over the three years of the study.
The researchers now want to use the vaccine, called CAD106, in a larger clinical trial to see if they get the same results.